Get started
Author

Alan J. Swaisland

Observed names: A Swaisland, A. J. Swaisland, A. SWAISLAND, A. Swaisland, A.J. Swaisland, Alan Swaisland
Observed institutions: AstraZeneca (United Kingdom), Universitat Autònoma de Barcelona, Institute of Cancer Research, Chulalongkorn University, Universitat de València, Kyoto Pharmaceutical University, Royal Bournemouth Hospital, Poole Hospital, Edinburgh Cancer Research, Radboud University Medical Center, University of Chicago Medical Center, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Royal Marsden Hospital, Duke Medical Center, Vall d'Hebron Hospital Universitari, Centre Hospitalier de l’Université de Montréal, AstraZeneca (United States), Duke University Hospital, Bicêtre Hospital, Vall d'Hebron Institute of Oncology
OpenAlex ID: A5074809692
Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide
1974 · P. SIMS, P. L. GROVER, et al. · Nature · 1,134
Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
2009 · J. Simon W. Stewart, Ezra E.W. Cohen, et al. · Journal of Clinical Oncology · 381
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
2006 · David A. Reardon, Jennifer A. Quinn, et al. · Clinical Cancer Research · 191
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial
2009 · Rosemary A Hannon, Glen Clack, et al. · Journal of Bone and Mineral Research · 110
PDF
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
2010 · José Baselga, Andres Cervantes, et al. · Clinical Cancer Research · 109
Polycyclic hydrocarbon epoxides: The involvement of 8,9‐dihydro‐8,9‐dihydroxybenz (a) anthracene 10,11‐oxide in reactions with the DNA of benz (a) anthracene‐treated hamster embryo cells
1974 · A.J. Swaisland, A. Hewer, et al. · FEBS Letters · 84
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
2009 · Yuri Rukazenkov, Georgina Speake, et al. · Anti-Cancer Drugs · 59
Some properties of “K-region” epoxides of polycyclic aromatic hydrocarbons
1973 · Alan J. Swaisland, Philip L. Grover, et al. · Biochemical Pharmacology · 43
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study
2007 · I. Chau, D. Cunningham, et al. · Annals of Oncology · 40
PDF
Gefitinib–phenytoin interaction is not correlated with the14C‐erythromycin breath test in healthy male volunteers
2009 · Stephanie Chhun, Celine Verstuyft, et al. · British Journal of Clinical Pharmacology · 39
PDF
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
2011 · Jiri Horak, Jeff White, et al. · Cancer Chemotherapy and Pharmacology · 35
Reactions of polycyclic hydrocarbon epoxides with RNA and polyribonucleotides
1974 · Alan J. Swaisland, Philip L. Grover, et al. · Chemico-Biological Interactions · 16
The effects of a selective 5‐HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.
1992 · DS Millson, CL Jessup, et al. · British Journal of Clinical Pharmacology · 14
PDF
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
2011 · Mitchell E. Gross, Lawrence Leichman, et al. · Cancer Chemotherapy and Pharmacology · 13
A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
2008 · T. Trarbach, J. Drevs, et al. · Journal of Clinical Oncology · 7
Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.
2010 · R Neil Dalton, Raj Chetty, et al. · PubMed · 4
Erratum: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial
2012 · Rosemary A Hannon, Glen Clack, et al. · Journal of Bone and Mineral Research · 1
Supplementary Data from Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
2023 · José Baselga, Andres Cervantes, et al.
PDF
Data from Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
2023 · José Baselga, Andres Cervantes, et al.
Data from Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
2023 · José Baselga, Andres Cervantes, et al.
Supplementary Data from Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
2023 · José Baselga, Andres Cervantes, et al.
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy
2006 · T. Hickish, I. Chau, et al. · Journal of Clinical Oncology
Abstracts of Dutch doctoral theses
1988 · G. J. Navis, G. J. Sterk, et al. · Pharmacy World & Science
Abstracts of posters symposium disposition and delivery of peptide drugs
1988 · H. Bundgaard, J. D. Larsen, et al. · Pharmacy World & Science
Works count: 24
Citation count: 2,280
H-index: 13
I10-index: 14
Year
Topic
Type